J&J vaccine lasts at least 8 months, protects against Delta variant, studies find

Johnson & Johnson shared data suggesting its COVID-19 vaccine lasts at least eight months and protects against the latest Delta variant.

The company produced one of the most popular COVID-19 vaccines and created the first single-shot option. For the past eight months, J&J has gathered blood samples from participants in an ongoing study. “Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.

J&J’s statement reads, “Johnson & Johnson single-shot COVID-19 vaccine-elicited neutralizing antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant.” Regarding the effective timespan of inoculation, the company said, “… humoral and cellular immune responses …  lasted through at least eight months, the latest timepoint recorded. Data showed that T-cell responses – including CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined.”

Other popular vaccines, such as Pfizer and Moderna have studies suggesting at least 6 months of efficacy. No COVID-19 vaccine has yet to gain full authorization from the Food and Drug Administration. 



The following two tabs change content below.
Antoinette is a community college student in Sacramento, California. She is a Politics Editor at Fact Based America, a correspondent for Campus Reform, and a student journalist. She previously worked for Turning Point USA as a High School Coordinator.

Leave a Reply